Business Description
Novo Nordisk AS
ISIN : US6701002056
Share Class Description:
NVO: ADRTotal Employee Number:
69,500Compare
Compare
Traded in other countries / regions
NOVO B.DenmarkNVO.USA0QIU.UKNOV.GermanyNOVO.CanadaN1VO34.BrazilNNO2.AustriaNVON.MexicoNOV.BulgariaNVO.Poland IPO Date
1981-04-30Description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.63 | |||||
Debt-to-EBITDA | 0.84 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.97 | |||||
Beneish M-Score | -2.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.3 | |||||
3-Year EBITDA Growth Rate | 27.8 | |||||
3-Year EPS without NRI Growth Rate | 25.8 | |||||
3-Year FCF Growth Rate | -22.7 | |||||
3-Year Book Growth Rate | 33 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.54 | |||||
9-Day RSI | 47.39 | |||||
14-Day RSI | 47.08 | |||||
3-1 Month Momentum % | 13.64 | |||||
6-1 Month Momentum % | 3.86 | |||||
12-1 Month Momentum % | -8.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.87 | |||||
Quick Ratio | 0.66 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 281.1 | |||||
Days Sales Outstanding | 85.84 | |||||
Days Payable | 565.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.89 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | 27.8 | |||||
Forward Dividend Yield % | 3.89 | |||||
5-Year Yield-on-Cost % | 11.31 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 1.74 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.65 | |||||
Operating Margin % | 43.13 | |||||
Net Margin % | 35.35 | |||||
EBITDA Margin % | 50.49 | |||||
FCF Margin % | 14.37 | |||||
OCF Margin % | 39.98 | |||||
ROE % | 60.88 | |||||
ROA % | 21.63 | |||||
ROIC % | 23.85 | |||||
3-Year ROIIC % | 20.71 | |||||
ROC (Joel Greenblatt) % | 72.27 | |||||
ROCE % | 47.61 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 9 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.39 | |||||
Forward PE Ratio | 13.36 | |||||
PE Ratio without NRI | 12.76 | |||||
Shiller PE Ratio | 19.73 | |||||
Price-to-Owner-Earnings | 10.19 | |||||
PEG Ratio | 0.49 | |||||
PS Ratio | 4.03 | |||||
PB Ratio | 5.97 | |||||
Price-to-Tangible-Book | 13.32 | |||||
Price-to-Free-Cash-Flow | 27.74 | |||||
Price-to-Operating-Cash-Flow | 10.07 | |||||
EV-to-EBIT | 9.47 | |||||
EV-to-Forward-EBIT | 11.39 | |||||
EV-to-EBITDA | 8.5 | |||||
EV-to-Forward-EBITDA | 9.96 | |||||
EV-to-Revenue | 4.29 | |||||
EV-to-Forward-Revenue | 4.89 | |||||
EV-to-FCF | 29.85 | |||||
Price-to-GF-Value | 0.43 | |||||
Price-to-Projected-FCF | 1.29 | |||||
Price-to-DCF (Earnings Based) | 0.51 | |||||
Price-to-DCF (FCF Based) | 1.8 | |||||
Price-to-Median-PS-Value | 0.52 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.51 | |||||
Price-to-Graham-Number | 2.75 | |||||
Earnings Yield (Greenblatt) % | 10.56 | |||||
FCF Yield % | 3.59 | |||||
Forward Rate of Return (Yacktman) % | 24.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:NVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novo Nordisk AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51,267.578 | ||
| EPS (TTM) ($) | 4.072 | ||
| Beta | 1.0007 | ||
| 3-Year Sharpe Ratio | -0.27 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 52.4 | ||
| 14-Day RSI | 47.08 | ||
| 14-Day ATR ($) | 1.511159 | ||
| 20-Day SMA ($) | 47.3975 | ||
| 12-1 Month Momentum % | -8.14 | ||
| 52-Week Range ($) | 35.12 - 64.16 | ||
| Shares Outstanding (Mil) | 4,422.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novo Nordisk AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novo Nordisk AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-04 07:00 | In 169 days | ||
| Annual report for 2026 | 2027-02-04 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-04 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 76 days | ||
| USD 0.578578 Cash Dividend | 2026-08-17 | 45.89 (-2.14%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 07:00 | 44.28 (-6.95%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 44.28 (-6.95%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 13:00 | 44.87 (+0.77%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 44.87 (+0.77%) |
Show
Entries
Novo Nordisk AS Frequently Asked Questions
What is Novo Nordisk AS(NVO)'s stock price today?
The current price of NVO is $46.36. The 52 week high of NVO is $64.16 and 52 week low is $35.12.
When is next earnings date of Novo Nordisk AS(NVO)?
The next earnings date of Novo Nordisk AS(NVO) is 2026-11-04.
Does Novo Nordisk AS(NVO) pay dividends? If so, how much?
The Dividend Yield %  of Novo Nordisk AS(NVO) is 3.89% (As of Today), Highest Dividend Payout Ratio of Novo Nordisk AS(NVO) was 0.62. The lowest was 0.39. And the median was 0.46. The  Forward Dividend Yield % of Novo Nordisk AS(NVO) is 3.89%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:NVO
Press Release
Articles on Novo Nordisk AS
Headlines
See More- 1
Aug 18, 2026
President boasts of drug savings with Most Favored Nation policy, TrumpRx
Seeking Alpha • 1:47pm
Hims CEO responds to FTC suit, sees GLP-1 prices falling to $40-$50: CNBC
Seeking Alpha • 1:44pm
Nestlé said to use AI tools to develop new products tailored to GLP-1 users
Seeking Alpha • 4:17am
Aug 11, 2026
Eli Lilly’s weight-loss pill gets first European approval in U.K.
Seeking Alpha • 3:23am
Aug 09, 2026
Top global stories this week: BP, SoftBank among notable names
Seeking Alpha • 8:00am
Aug 07, 2026
Lilly, Novo antitrust case over GLP-1s dismissed in Texas
Seeking Alpha • 10:08am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers